申请人:BAYER PHARMA AG
公开号:WO2017216025A1
公开(公告)日:2017-12-21
The present invention covers crystalline, anhydrous (2R)-2-(4-fluorophenyl)-N-[4-(2-[2- methoxy-4-(methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]propan- amide 4-toluenesulfonate, and crystalline (2R)-2-(4-fluorophenyl)-N-[4-(2-[2-methoxy-4- (methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]propanamide 4- toluenesulfonate monohydrate, as compounds per se, a method of preparing said crystalline, anhydrous compound, pharmaceutical compositions and pharmaceutical combinations comprising said crystalline, anhydrous compound, and uses of said crystalline, anhydrous compound in the treatment or prophylaxis of a cancer, in particular pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer, and/or gastric cancer.
本发明涵盖了结晶的、无水的(2R)-2-(4-氟苯基)-N-[4-(2-[2- 甲氧基-4-(甲磺酰基)苯基]氨基}[1,2,4]三唑[1,5-a]吡啶-6-基)苯基]丙酰胺对甲苯磺酸盐,以及结晶的(2R)-2-(4-氟苯基)-N-[4-(2-[2-甲氧基-4-(甲磺酰基)苯基]氨基}[1,2,4]三唑[1,5-a]吡啶-6-基)苯基]丙酰胺对甲苯磺酸盐一水合物,作为化合物本身,一种制备所述结晶的、无水的化合物的方法,包括所述结晶的、无水的化合物的药物组合物和药物组合物,以及所述结晶的、无水的化合物在治疗或预防癌症,特别是胰腺癌、胶质母细胞瘤、卵巢癌、非小细胞肺癌、乳腺癌和/或胃癌中的用途。